Abstract
Patients with pulmonary nontuberculous mycobacteriosis (pNTM) may have suboptimum response to conventional antimicrobial therapy. Aerosolized amikacin (aeAmk) was given to nine patients who had failed standard combination oral antimycobacterial drugs. A favorable toxicity profile, even in patients given aeAmk for an extended duration, median 75 ± 85 (range, 18–277) days and total cumulative dose 35,400 ± 30,568 (range, 7,600–95,400) mg, was encouraging, as was the clinical response and resolution of symptoms in 8 of 9 patients. The patient who failed therapy died due to complications arising from prior hematopoietic transplantation. The feasibility and efficacy of aeAmk in combination with oral anti-NTM drug(s) for treatment-refractory disease and, importantly, in primary therapy for pNTM requires validation randomized trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP (2008) Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 63:627–634
Rodriguez G, Safdar A. Nontuberculous mycobacterial lung disease: a difficult-to-treat clinical syndrome of increasing significance in patients at a comprehensive cancer center (under review)
Research Committee of the British Thoracic Society (2001) First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56:167–172
Ghannam DE, Rodriguez GH, Raad II, Safdar A (2009) Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 28:253–259
Han XY, Pham AS, Tarrand JJ, Sood PK, Luthra R (2002) Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol 118:796–801
National Committee for Clinical Laboratory Standards (NCCLS) (2003) Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes; approved standard. M24-A. NCCLS, Wayne, PA
Woods GL (2000) Susceptibility testing for mycobacteria. Clin Infect Dis 31:1209–1215
American Thoracic Society (ATS) (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 156(2 Pt 2):S1–S25
Safdar A, White DA, Stover D, Armstrong D, Murray HW (2002) Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 113:756–759
Safdar A, Armstrong D, Murray HW (2003) A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med 138:521
Davis KK, Kao PN, Jacobs SS, Ruoss SJ (2007) Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 7:2
Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y et al (2008) Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 178:1066–1074
Waller EA, Roy A, Brumble L, Khoor A, Johnson MM, Garland JL (2006) The expanding spectrum of Mycobacterium avium complex-associated pulmonary disease. Chest 130:1234–1241
Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108(Suppl 1):4554–4561
Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D (2004) Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38:1538–1544
Rodriquez GH, Rallapalli V, Safdar A. Aerosolized amphotericin B lipid complex for salvage therapy in cancer patients with difficult-to-treat pulmonary fungal disease (under review)
Safdar A, O’Brien S, Kouri IF (2004) Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 34:467–468
Safdar A (2010) Feasibility of aerosolized colistin in the era of escalating drug-resistant Pseudomonas pneumonia: pressing need for validation clinical trials. Intensive Care Med 36:1110–1111
Rastogi N, Goh KS, Bryskier A, Devallois A (1996) Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 40:2483–2487
Alcaide F, Calatayud L, Santín M, Martín R (2004) Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 48:4562–4565
Alvarez-Elcoro S, Enzler MJ (1999) The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 74:613–634
Griffith DE, Wallace RJ Jr (1996) New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect 11:301–310
Glassroth J (2008) Pulmonary disease due to nontuberculous mycobacteria. Chest 133:243–251
Acknowledgment
Dr. Gilhen Rodriguez of The University of Texas Medical Center provided invaluable support in obtaining the data for this report.
Conflict of interest
There was no grant support for this work and there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Safdar, A. Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis. Eur J Clin Microbiol Infect Dis 31, 1883–1887 (2012). https://doi.org/10.1007/s10096-011-1516-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-011-1516-3